Pocket Medicine: The Massachusetts General Hospital Handbook of Internal Medicine (59 page)

BOOK: Pocket Medicine: The Massachusetts General Hospital Handbook of Internal Medicine
4.96Mb size Format: txt, pdf, ePub
? ↑ diuresis w/ co-administration of albumin if ↓ serum albumin (
Crit Care Med
2005;33:1681)

Thiazide diuretics
(
NEJM
2009;361:2153)

Drugs
: hydrochlorothiazide (HCTZ), chlorothiazide (Diuril), metolazone (Zaroxolyn) •
Mechanism
: inhibit Na-Cl cotransporter in the distal convoluted tubule (DCT)

synergistic with loop diuretic
, esp. if chronic loop use
↓ effect when GFR <30,
except metolazone
which is still effective in renal insufficiency

Dosing
: give prior to loop diuretic, typically ~30 min before
K-sparing diuretics

Drugs
: spironolactone (Aldactone), amiloride, triamterene, eplerenone •
Mechanism
: ↓ Na reabsorption in collecting duct (amiloride/triamterene inhibit principal cell Na channel [ENaC]; spironolactone/eplerenone inhibit mineralocorticoid receptor). Relatively weak natriuretic activity, useful in combination with thiazide or in cirrhosis.

Disease state specific regimens

• Renal insufficiency: loop diuretic (↑ dose to achieve effective delivery to ThAL) ± thiazide • CHF: loop diuretic (↑ frequency over ↑ dose) + thiazide (watch K & Mg) • Nephrotic syndrome: urinary albumin binds secreted loop diuretic, use 2–3 × normal dose • Cirrhosis: spironolactone (blocks 2° hyperaldosteronism) + lasix in 2.5:1 ratio • Severe metabolic alkalosis: acetazolamide & treat underlying cause
Adverse effects
• Loop: ± ↑ Na, ↓ K, ↓ Mg, ↓ Ca, hyperuricemia, ototoxicity, hypersensitivity (sulfa) • Thiazide: ↓ Na, ↓ K, ↓ Mg, ↑ Ca, hyperlipidemia, pancreatitis, ↑ glucose • K-sparing: ↑ K (esp. w/ ACEI), metabolic acidosis, gynecomastia (spironolactone)

RENAL REPLACEMENT AND DIALYSIS

General

• Substitutes for renal solute and fluid removal;
Acute:
CVVH vs. HD;
Chronic:
PD vs. HD

Hemodialysis (HD)
(
NEJM
2010;363:1833)
• Physiology: blood flows along one side of
semipermeable
membrane, dialysate along other

Fluid removal (ie, Na + H
2
O) via transmembrane pressure (TMP) gradient
Solute removal via transmembrane concentration gradient and inversely proportional to size (∴ effective removal of K, urea, and Cr, but not PO
4
)
• Typical orders: duration, volume removal goals, K and Ca in dialysate bath, anticoagulation • 6× vs. 3×/wk improved HTN, LV mass, QoL, but ↑ vasc issues (
NEJM
2010;363:2287); w/ 3×/wk HD, ↑ adverse outcomes after 2 d interval (
NEJM
2011;365:1099) • Complications: HoTN, arrhythmia, access issues (clot, stenosis, infxn, recirculation), disequilibrium syndrome (sx of cerebral edema due to H
2
O shifts after removal of plasma urea during dialysis, esp. in new HD Pts w/ ↑ ↑ BUN), high output HF
• Fever w/ catheter: empiric abx (vanc + AG qHD). GPC > GNR > mixed/fungal. Catheter removal, replacement, or “lock” abx. Consider metastatic infxn w/u (
AJKD
2004;44:779).

Continuous veno-venous hemofiltration (CVVH)
(
NEJM
2012;367:26)
• Physiology:
hemofiltration
rather than dialysis. Blood under pressure passes down one side of
highly permeable
membrane allowing H
2
O and solutes to pass across membrane via TMP gradient (convective clearance). Filtrate discarded. Replacement fluid infused (solute concentrations similar to plasma, except no K, urea, Cr, PO
4
). Fluid balance precisely controlled by adjusting filtrate/replacement fluid.

• Access: double-lumen central venous catheter • Typical orders: volume goals, replacement fluid buffer:
HCO
3
(requires heparin to prevent machine from clotting)
vs. citrate
(hepatically metabolized to HCO
3
; provides anticoagulation w/ in machine via Ca chelation; ∴ requires Ca infusion) • Complications: hypotension, ↓ PO
4
, access complications; ↓ ICa (citrate toxicity in Pts with hepatic dysfunction → look for ↓ ICa but normal/ ↑ serum Ca and AG met acidosis) • Potential advantages over HD: less hypotension, better volume control, removal of inflammatory mediators; however, no survival advantage (
Lancet
2006;368:379) • No advantage for high intensity CVVH over standard intensity (
NEJM
2008;359:7)
Peritoneal dialysis (PD)
(
Perit Dial Int
2001;21:25)
• Physiology: peritoneum acts as membrane. Fluid balance controlled by choosing dialysate [glc] (higher concentrations pull more fluid into peritoneum); longer dwell times pull less fluid as glc equilibrates across peritoneum • Access: permanent catheter inserted in OR
• Typical orders for CAPD (continuous ambulatory peritoneal dialysis):
PD fluid = dextrose (1.5%, 2.5%, or 4.25%), buffer (lactate), Na+, Ca
2
+, Mg
2
+
infuse 10 min, dwell 90 min–5.5 h, drain 20 min
• Can use overnight cycler device that infuses & drains more rapidly, with shorter dwells, while Pt sleeps. Called automated or continuous cycling peritoneal dialysis (APD, CCPD).
• Complications: hypoalbuminemia; right-sided pleural effusion Peritonitis: abd pain, tenderness, cloudy drainage (WBC >100 and >50% PMNs) spectrum: 60–70% GPC, 15–20% GNR, remainder no bacteria or fungal Rx: abx IV or in PD, catheter removal for certain pathogens (eg, yeast,
Pseudomonas
) Hyperglycemia: exacerbated by inflammation, long dwell times, and higher [glc]

Kidney transplantation
(
NEJM
1994;331:365)
• Rx of choice for ESRD; contraindic: active malig, infxn, ischemia, noncompl, subst abuse • Immunosuppression: calcineurin inhib (tacrolimus, CsA), antimetabolite (AZA, MMF), prednisone, ± mTOR inhibitor (sirolimus) (
NEJM
2004;351:2715) • Late renal dysfxn: usual AKI causes + calcineurin tox, rejection, BK virus, recurrence of 1° disease; usual w/u + immunosupp levels, BK virus load, U/S, then bx if no other cause • ↑ risk of infxn (incl opportunistic such CMV, JC, BK viruses) & malignancy (incl PTLD) • ↑ CVD risk due to HTN (calcineurin inhib, RAS), DM & dyslipidemia (immunosupp meds)

GLOMERULAR DISEASE

GLOMERULONEPHRITIS (GN)

Definition
(
NEJM
1998;339:888;
Lancet
2005;365:1797)

Pathologically:
intraglomerular inflammation (ranging from focal proliferative [<50% of glomeruli] to diffuse proliferative to crescentic) (
Lancet
2006;368:404) •
Clinically:
hematuria w/ dysmorphic RBCs or RBC casts, ± subnephrotic proteinuria

often w/ renal failure, HTN, edema

Progression:
acute GN
days; rapidly progressive GN (RPGN)
wks; chronic GN
mos; can simply have asx hematuria • Crescentic GN (pathologic description)
RPGN (clinical description)

Other books

Take My Hand by Haken, Nicola
Entranced by Jessica Sorensen
Veracity by Laura Bynum
Finding Focus by Jiffy Kate
The Girl from the Garden by Parnaz Foroutan
Miss Manners by Iman Sid
Rivers: A Novel by Michael Farris Smith
Project U.L.F. by Stuart Clark